Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  ValGenesis Inc., the market leader ... that it has completed its Service Organization Controls 2 ... (AICPA, Professional Standards) for the period of January 1 ... ... The SOC 2 examination is ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/8dzk58/blood_screening ) ... Screening Market by Technology (Nucleic Acid Amplification Test, ... Western Blotting), Product (Instrument, Reagent) & End User ... report to their offering. The ... billion by 2019 from $1.5 billion in 2014, ...
(Date:4/1/2015)... NEW YORK , April 1, 2015 ... biopharmaceutical company advancing protein biologic therapies and oncology ... the Company,s 2014 achievements and a strategic update ... progress the Company has made in the areas ... its MuGard programs, the FDA clearance of the ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 The concept ... loss, a multi-billion dollar industry. Founder of Fasciology, Ashley Black, ... an area of fat, instead of having to wait for ... Black claims that “ prior to fat cooling procedures, ... sculpting or contouring, was liposuction, which is a highly invasive ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... operating income of $856,000, IRVINE, Calif., March ... developer of surgical products,and accessories used in angina-relieving ... and fiscal year ended December 31,2007., Sales ... a 24% decrease,from the prior year fourth quarter ...
... FRANCISCO, March 25 Medivation, Inc.,(Nasdaq: MDVN ... Bronson, Ph.D.,to vice president, regulatory and quality, Mohammad ... Mordenti, Ph.D., to vice,president, translational medicine., "As ... product candidate, we are,strengthening the team to lead ...
... MARINO, Calif., March 25 Epeius Biotechnologies,Corporation ... No. 7,347,998 for,Targeted Gene Delivery in vivo. ... the platform of highly advanced,biotechnologies embodied in ... by simple intravenous infusion, the Epeius,tumor-targeted gene ...
Cached Biology Technology:Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 7Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... recently discovered form of the protein that triggers blood ... of metastatic pancreatic cancer and primary breast cancer, according ... published online ahead of print in the International ... Proceedings of the National Academy of Sciences ). ...
... and hope to be a father, here,s another reason ... your waistline or metabolic disorders. That,s because scientists have ... did not show any signs of diabetes, passed this ... Sons don,t entirely dodge this genetic bullet eitherboth sons ...
... and the National Institutes of Health have obtained ground-breaking new ... play a role in the development of cancer cells. The ... and have just been published in Journal of Biological ... of proteases to force their way into the body., In ...
Cached Biology News:Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests 2Obese dads pass on predisposition to obesity and metabolic disorders to their kids 2Molecular discovery puts cancer treatment in a new perspective 2Molecular discovery puts cancer treatment in a new perspective 3